Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo
- PMID: 30287265
- DOI: 10.1016/j.jconrel.2018.09.031
Nano-targeted relaxin impairs fibrosis and tumor growth in pancreatic cancer and improves the efficacy of gemcitabine in vivo
Abstract
Cancer-associated fibroblasts (CAFs), are the key effector cells in pancreatic ductal adenocarcinoma (PDAC), known to induce tumor growth and progression. Pancreatic stellate cells (PSCs) are the precursors of CAFs in PDAC that secrete abundant extracellular matrix, growth factors and cytokines. In this study, we targeted human relaxin-2 (RLX), an endogenous hormone, to PSCs to inhibit their differentiation into CAF-like myofibroblasts. RLX significantly inhibited TGF-β induced PSCs differentiation by inhibiting pSmad2 signaling pathway. In vitro in primary human PSCs (hPSCs), treatment with RLX dose-dependently inhibited the migration, contraction, and protein expression of alpha smooth muscle actin and collagen I These data demonstrate that RLX can regulate hPSCs activation in vitro. However, RLX has several drawbacks i.e. poor pharmacokinetics and systemic vasodilation, that limits its preclinical and clinical application. Thus, we designed and successfully synthesized a nanoparticle system by chemically conjugating RLX to superparamagnetic iron oxide nanoparticle (SPION) to improve its pharmacokinetics. Interestingly, we found RLX-SPION to be more efficacious compared to free RLX in vitro. Significantly, we observed RLX-SPION retarded the tumor growth by itself and also potentiated the effect of gemcitabine in a subcutaneous co-injection (Panc1 and hPSCs) tumor model. The treatment resulted in significant inhibition in tumor growth, which was attributed to reduced collagen I (ECM), desmin (hPSC marker) and CD31 (endothelial marker) expression. In contrast, free RLX showed no significant effects. Altogether, this study presents a novel therapeutic approach against tumor stroma using RLX-SPION to achieve an effective treatment against pancreatic tumor.
Keywords: Cancer-associated fibroblasts; Pancreatic cancer; Pancreatic stellate cells; Relaxin-2; Superparamagnetic iron-oxide nanoparticles; Tumor stroma.
Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.
Similar articles
-
FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor.Nanotheranostics. 2020 Jan 1;4(1):26-39. doi: 10.7150/ntno.38092. eCollection 2020. Nanotheranostics. 2020. PMID: 31911892 Free PMC article.
-
Reprogramming tumor stroma using an endogenous lipid lipoxin A4 to treat pancreatic cancer.Cancer Lett. 2018 Apr 28;420:247-258. doi: 10.1016/j.canlet.2018.01.072. Epub 2018 Feb 21. Cancer Lett. 2018. PMID: 29408203
-
Integrin α11 in pancreatic stellate cells regulates tumor stroma interaction in pancreatic cancer.FASEB J. 2019 May;33(5):6609-6621. doi: 10.1096/fj.201802336R. Epub 2019 Feb 26. FASEB J. 2019. PMID: 30808244
-
Relaxin in hepatic fibrosis: What is known and where to head?Biochimie. 2021 Aug;187:144-151. doi: 10.1016/j.biochi.2021.06.001. Epub 2021 Jun 5. Biochimie. 2021. PMID: 34102254 Review.
-
Fibrotic Fortresses and Therapeutic Frontiers: Pancreatic Stellate Cells and the Extracellular Matrix in Pancreatic Cancer.Cancer Med. 2025 Jun;14(11):e70788. doi: 10.1002/cam4.70788. Cancer Med. 2025. PMID: 40437741 Free PMC article. Review.
Cited by
-
Development of Dual Diagnostic-Therapeutic Nanoformulation Effective Against Pancreatic Cancer in Animal Model.Int J Nanomedicine. 2024 Sep 6;19:9121-9143. doi: 10.2147/IJN.S464788. eCollection 2024. Int J Nanomedicine. 2024. PMID: 39258004 Free PMC article.
-
Signaling pathways in cancer-associated fibroblasts: recent advances and future perspectives.Cancer Commun (Lond). 2023 Jan;43(1):3-41. doi: 10.1002/cac2.12392. Epub 2022 Nov 24. Cancer Commun (Lond). 2023. PMID: 36424360 Free PMC article. Review.
-
The Application of Nanoparticles Targeting Cancer-Associated Fibroblasts.Int J Nanomedicine. 2024 Apr 8;19:3333-3365. doi: 10.2147/IJN.S447350. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38617796 Free PMC article. Review.
-
Nano-Drug Delivery Systems Targeting CAFs: A Promising Treatment for Pancreatic Cancer.Int J Nanomedicine. 2024 Mar 18;19:2823-2849. doi: 10.2147/IJN.S451151. eCollection 2024. Int J Nanomedicine. 2024. PMID: 38525013 Free PMC article. Review.
-
Development of nanoscale drug delivery systems of dihydroartemisinin for cancer therapy: A review.Asian J Pharm Sci. 2022 Jul;17(4):475-490. doi: 10.1016/j.ajps.2022.04.005. Epub 2022 May 14. Asian J Pharm Sci. 2022. PMID: 36105316 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical